全文获取类型
收费全文 | 16123篇 |
免费 | 1065篇 |
国内免费 | 339篇 |
专业分类
耳鼻咽喉 | 40篇 |
儿科学 | 447篇 |
妇产科学 | 138篇 |
基础医学 | 2283篇 |
口腔科学 | 114篇 |
临床医学 | 902篇 |
内科学 | 2391篇 |
皮肤病学 | 101篇 |
神经病学 | 128篇 |
特种医学 | 114篇 |
外国民族医学 | 1篇 |
外科学 | 421篇 |
综合类 | 1324篇 |
现状与发展 | 1篇 |
一般理论 | 2篇 |
预防医学 | 7068篇 |
眼科学 | 42篇 |
药学 | 1131篇 |
6篇 | |
中国医学 | 71篇 |
肿瘤学 | 802篇 |
出版年
2024年 | 23篇 |
2023年 | 593篇 |
2022年 | 1013篇 |
2021年 | 933篇 |
2020年 | 780篇 |
2019年 | 671篇 |
2018年 | 694篇 |
2017年 | 610篇 |
2016年 | 631篇 |
2015年 | 713篇 |
2014年 | 822篇 |
2013年 | 1203篇 |
2012年 | 870篇 |
2011年 | 1015篇 |
2010年 | 823篇 |
2009年 | 796篇 |
2008年 | 503篇 |
2007年 | 660篇 |
2006年 | 576篇 |
2005年 | 506篇 |
2004年 | 470篇 |
2003年 | 418篇 |
2002年 | 324篇 |
2001年 | 289篇 |
2000年 | 248篇 |
1999年 | 233篇 |
1998年 | 156篇 |
1997年 | 158篇 |
1996年 | 110篇 |
1995年 | 79篇 |
1994年 | 69篇 |
1993年 | 64篇 |
1992年 | 48篇 |
1991年 | 53篇 |
1990年 | 49篇 |
1989年 | 56篇 |
1988年 | 44篇 |
1987年 | 34篇 |
1986年 | 36篇 |
1985年 | 51篇 |
1984年 | 27篇 |
1983年 | 15篇 |
1982年 | 17篇 |
1981年 | 11篇 |
1980年 | 7篇 |
1979年 | 6篇 |
1978年 | 8篇 |
1977年 | 3篇 |
1976年 | 2篇 |
1974年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
81.
82.
Effects of Killed and Live Attenuated Influenza Vaccine on Symptoms and Specific Airway Conductance in Asthmatics and Healthy Subjects 总被引:1,自引:0,他引:1
Killed and live influenza virus vaccines were given to asthmatics and healthy subjects to investigate symptoms and alterations in their respiratory performance after vaccination. Polyvalent killed influenza virus vaccine was given to 16 asthmatics and live attenuated influenza virus vaccine to 23 asthmatics and 21 healthy subjects. Fourteen of the 16 asthmatics vaccinated with the killed vaccine displayed a significant rise in serum antibody level as measured by a single radial haemolysis in gel (SRH test). 11 of the 23 asthmatics and 14 of the 21 healthy subjects vaccinated with the live attenuated vaccine displayed a significant rise in the SRH test. Among the subjects with no measurable initial antibodies and with a significant rise in the SRH test, one asthmatic vaccinated with the killed vaccine experienced symptoms of common cold with fever and dyspnoea 1 week after vaccination. Three asthmatics and four healthy subjects vaccinated with live attenuated vaccine experienced mild symptoms, mainly rhinorrhoea, cough and sore throat 2 to 3 days after vaccination. No alterations in specific airway conductance in asthmatics or in healthy subjects were observed. We conclude that both killed and live attenuated influenza virus vaccines are tolerated well by asthmatics and appear to be safe for asthma patients. 相似文献
83.
GM-CSF对MUC1基因疫苗抑制乳腺癌生长的增强作用 总被引:5,自引:2,他引:5
目的 :观察GM CSF有无增强MUC1基因疫苗对EMT6乳腺癌生长的特异性抑制作用。方法 :采用股四头肌肌肉注射法 ,将构建的MUC1基因疫苗pcDNA3.1 MUC1免疫雌性BALB/c小鼠 ,每 3wk 1次 ,共 3次。每次基因免疫后 1、3、5d ,皮下注射GM CSF 10 0 μL(1μg/ 10 0 μL)。最后 1次基因免疫后第 3周 ,接种表达MUC1的EMT6小鼠乳腺癌细胞。两周后观察、记录肿瘤的生长情况。于肿瘤细胞接种后第 4 3天 ,处死全部动物 ,称量肿瘤的质量。用 4h51Cr释放法检测小鼠脾特异性CTL的杀伤活性。结果 :接种肿瘤细胞后 4 3d ,MUC1基因疫苗加GM CSF组、MUC1基因疫苗组、pcDNA3.1加GM CSF组及pcDNA3.1组 ,EMT6肿瘤的大小依次为 (135± 33.8)mm3 、(2 5 0± 34.3)mm3 、(5 6 8± 4 3.6 )mm3 和 (5 96± 4 8.2 )mm3 ;平均瘤质量 (g)依次为 (0 .81± 0 .4 2 )g、(1.2 3± 0 .4 1)g、(2 .30± 0 .4 8)g及 (2 .2 8± 0 .5 8)g。与对照组相比较 ,MUC1基因疫苗组EMT6肿瘤的生长受到明显抑制 (P <0 .0 5 ) ;与单独MUC1基因疫苗组相比较 ,MUC1基因疫苗加GM CSF组抗肿瘤生长的作用有显著差异 (P <0 .0 5 )。在效靶比为 10 0∶1、5 0∶1、2 5∶1和 12 .5∶1时 ,MUC1基因疫苗加GM CSF组特异性CTL对EMT6靶细胞的杀伤率 ,依次为 6 8.5 %、 5 3.4 % 相似文献
84.
A rapid passive hemagglutination assay (Rubaquick) was developed that detects antibody to rubella virus in serum specimens. The test result is read visually after an incubation period of 15-30 minutes. When compared with a hemagglutination inhibition assay, the Rubaquick assay results obtained from 1,470 sera were greater than 99% specific, sensitive, and accurate. Studies of 179 paired serum specimens obtained before and 27 days after rubella vaccination showed that if antibody was detectable by the Rubaquick assay in the prevaccination specimens, the vaccine induced a secondary response consisting of increasing IgG antibody reactivity in the absence of a positive IgM response. In contrast to the positive prevaccination specimens, a negative prevaccination result was associated with IgM antibody in 98 of the 133 postvaccination specimens. Seroconversion was noted in all cases in which the prevaccination specimen was negative by the Rubaquick assay. 相似文献
85.
Amara RR Ibegbu C Villinger F Montefiori DC Sharma S Nigam P Xu Y McClure HM Robinson HL 《Virology》2005,343(2):246-255
Here, we study immune responses in four DNA/MVA-vaccinated macaques following an SHIV-89.6P challenge and a subsequent CD8 cell depletion. Both post-challenge and post-depletion peaks of viremia contracted with the expansion, or re-emergence, of CD8 T cells. Post-depletion, CD8 cells expanded in the presence of higher levels of neutralizing Ab and CD4 help than post-challenge and had superior maturational characteristics as measured by expression of the anti-apoptotic protein Bcl-2, the IL-7 receptor CD127 and co-production of IFN-gamma and IL-2. Pre-challenge and pre-depletion titers of neutralizing Ab correlated inversely with peaks of viremia and directly with peaks for anti-viral CD4 cells. Thus, our results reveal CD8 cells playing a central role, and neutralizing Ab, a supporting role in SHIV-89.6P control. They also suggest a dynamic relationship between neutralizing Ab, antigen load and anti-viral CD4 cells in the maturation of high-quality anti-viral CD8 T cells. 相似文献
86.
目的 :应用四环素 (tetracycline,Tet)可调控系统建立可调控的抗恶性疟原虫的DNA疫苗。方法 :首先构建恶性疟原虫顶端膜抗原 1(AMA 1)基因和转录激活因子 (tTA或rtTA)基因的真核表达质粒pTL 8/AMA 1和pTL 8/AMA 1(rtTA) ,并大量制备这两种质粒及表达转录抑制子 (tTS)的质粒pUHS6 1。以pTL 8/AMA 1、pTL 8/AMA 1(rtTA)和pTL 8/AMA 1(rtTA)加pUHS6 1/tTS免疫小鼠后 ,用四环素类似物强力霉素 (doxcycline ,dox)诱导或抑制上述DNA载体内AMA 1的表达 ,并分离小鼠血清检测针对AMA 1抗体的表达情况。结果 :①构建了真核表达质粒pTL 8/AMA 1和pTL 8/AMA 1(rtTA) ;②pTL 8/AMA 1和pTL 8/AMA 1(rtTA)在没有被诱导表达时 (仅基础表达 ) ,可诱导明显的免疫应答。在以pTL 8/AMA 1(rtTA)与含tTS的pUHS6 1共同免疫后 ,可极大地降低其免疫应答。应用dox诱导pTL 8/AMA 1(rtTA)中的AMA 1基因表达后 ,可明显引起免疫应答。结论 :pTL 8/AMA 1(rtTA)附加pUHS6 1构成了可调节的DNA免疫系统。该系统的建立将对进一步深入研究DNA疫苗的免疫机制和调控基因表达 ,减少不良免疫反应以及进行可精确调控的基因治疗打下一定的基础 相似文献
87.
Chikhlikar P Barros de Arruda L Agrawal S Byrne B Guggino W August JT Marques ET 《Virology》2004,323(2):220-232
The immune responses to an HIV-1 p55Gag vaccine encoded as a DNA chimera with the lysosomal associated membrane protein-1 (LAMP) have been examined for the effect of the addition of the inverted terminal repeat (ITR) sequences of the adeno-associated virus (AAV) to the DNA plasmid construct, and of packaging the LAMP/gag gene as a recombinant AAV vector (rAAV). DNA plasmids encoding Gag and the LAMP/Gag protein chimera were constructed in two vectors, the pcDNA3.1 and a corresponding plasmid containing the ITR sequences (pITR) flanking the expression elements of the plasmid, and the pITR LAMP/gag DNA plasmid was encapsidated in the rAAV vector. Human 293 cells transfected in vitro with LAMP/gag plasmids either in pcDNA3.1 or pITR produced much Gag protein in cell extracts (1.6 and 2.2 ng of Gag/mg of protein, respectively). The immune responses of mice to immunization with these constructs were examined under three protocols: DNA prime/DNA boost, DNA prime/rAAV boost, and a single rAAV immunization. The results demonstrated that under DNA prime/DNA boost protocol, the "naked" DNA vaccines encoding the LAMP/gag chimera, either as pcDNA3.1 or pITR DNA plasmid constructs, elicited strong CD4(+) T cell responses. In contrast, significantly higher levels of CD8(+) and antibody responses were observed with the pITR-DNA constructs. Immunization with the rAAV vector under the DNA prime/rAAV boost protocol resulted in sustained T cell responses and a markedly increased antibody response, predominantly of the IgG(1) isotype resulting from the activation of the Th2 subset of CD4(+) T cells, that was sustained for at least 5 months after immunization. 相似文献
88.
Logan Banner Rao Ernstoff Wolmark Whiteside Miketic Kirkwood 《Clinical and experimental immunology》1998,114(3):347-354
A patient with von Hippel Lindau disease, bilateral symmetric renal cell carcinoma and pulmonary metastases treated with immunotherapy is the subject of this study. A left kidney and tumour mass were removed and the tumour cells used to make an autologous tumour/bacille Calmette–Guérin (BCG) vaccine as part of the treatment protocol. The patient's pulmonary nodules responded, but the remaining renal nodule subsequently grew. Samples of both tumours were obtained allowing for an internally controlled evaluation of the histological and immunohistologic differences between a responding and non-responding tumour nodule after therapy. The immunotherapy protocol is designed to promote a T cell response to autologous tumour. Cellular infiltrates were demonstrated in both responding and non-responding nodules compared with the pretreatment tumour specimen, but the responding nodule contained proportionately more T cells as well as markedly increased numbers of plasma cells and granulocytes. This suggested that several arms of the immune system may have been operative in the responding nodule. 相似文献
89.
90.
David P. Shrayer Bernard Cole Vincent J. Hearing Stanley F. Wolf Harold J. Wanebo 《Clinical & experimental metastasis》1999,17(1):73-80
Interleukin (IL)-12 can activate cytotoxic lymphocytes, stimulate natural killer cell activity, induce the production of INF- and inhibit the development of various experimental tumors. We previously demonstrated that immunotherapy of melanoma bearing mice with an irradiated melanoma vaccine (IMV) coupled with IL-2 or GM-CSF had beneficial effects against primary melanoma growth and against subsequent spontaneous metastasis. We also had found that treatment of melanoma bearing mice with IL-12 (300 ng/day) for 4 weeks inhibited the development of primary melanoma tumors in 40% of mice. The purpose of this study was to investigate the efficacy of combined therapy of experimental melanoma with an IMV prepared from B16F10 melanoma cells coupled with IL-12 treatment. C57BL/6 mice were challenged subcutaneously in the tail with B16F10 melanoma cells and by the 45th day, more than 50% of the mice had developed visible primary melanoma tumors at the injection site. Subsequent immunotherapy of mice with IMV, when coupled with IL-12, provided partial inhibition of primary melanoma tumor growth. Optimal results against primary tumor growth were observed when IMV therapy was coupled with IL-12 at a dose of 50 ng/day. Combination of IMV with IL-12 at a dose of 100 ng/day significantly reduced melanoma metastasis to the lungs compared with control mice, and an improvement in mean survival time was observed in mice treated with a combination of IMV with IL-12 (300 ng/day). 相似文献